Prime Medicine (PRME) Q3 2026 earnings summary

Executive summary

• Q3 2026 net loss narrowed to $39.0M from $50.6M YoY; 9M net loss was $130.3M versus $155.1M.

• Pipeline advanced into clinical development: PM577a’s first patient was dosed in October, while PM647 received FDA IND clearance in September; initial data for both are expected in 2027.

Financial highlights

• Q3 collaboration revenue was $4.2M versus $1.2M YoY; 9M revenue was $6.2M versus $3.8M, with no product-sale revenue to date.

• Q3 operating expenses were $44.1M versus $55.2M; operating loss was $39.9M versus $54.0M. 9M expenses were $140.1M versus $163.5M.

• 9M operating cash use was $120.4M; cash, cash equivalents and short-term investments were $61.2M at September 30, excluding restricted cash.

Outlook and guidance

• Existing cash, cash equivalents and investments, including November offering proceeds, are expected to fund operating expenses and capital needs through 2027; the estimate relies on assumptions that may prove incorrect.

• Initial clinical data for PM577a and PM647 are expected in 2027; a BLA submission for PM359 is planned for H1 2027.

• Operating losses and negative operating cash flows are expected for the foreseeable future; R&D spending may rise as trials and development advance.